A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer
- 1 May 2012
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 10 (5), 807-814
- https://doi.org/10.1111/j.1538-7836.2012.04693.x
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for CancerThe New England Journal of Medicine, 2012
- Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized TrialJournal of Clinical Oncology, 2011
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip ReplacementThe New England Journal of Medicine, 2010
- PRODIGE: a randomized placebo‐controlled trial of dalteparin low‐molecular‐weight heparin thromboprophylaxis in patients with newly diagnosed malignant gliomaJournal of Thrombosis and Haemostasis, 2010
- Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind studyThe Lancet Oncology, 2009
- Apixaban or Enoxaparin for Thromboprophylaxis after Knee ReplacementThe New England Journal of Medicine, 2009
- The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacementJournal of Thrombosis and Haemostasis, 2007
- American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With CancerJournal of Clinical Oncology, 2007
- Treatment of Venous Thromboembolism in Cancer PatientsSeminars in Thrombosis and Hemostasis, 1999
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancerThe Lancet, 1994